Moneycontrol
HomeNewsBusinessAirAsia shares plunge 11% after auditor flags 'going concern' doubts

AirAsia shares plunge 11% after auditor flags 'going concern' doubts

Ernst & Young issued an audit opinion stating that the airline's 2019 earnings were prepared on a going concern basis, which is dependent upon a recovery from the COVID-19 pandemic and the success of fundraising efforts.

July 08, 2020 / 15:53 IST
Story continues below Advertisement

Shares in Malaysia's AirAsia Group Bhd tumbled 11 percent on Wednesday after its auditor said there were material uncertainties that cast doubt on the budget carrier's ability to continue as a going concern.

Ernst & Young issued an audit opinion stating that the airline's 2019 earnings were prepared on a going concern basis, which is dependent upon a recovery from the COVID-19 pandemic and the success of fundraising efforts.

Story continues below Advertisement

In response, the airline said in a statement that Malaysia's stock exchange had granted it 12 months relief from being classified as a financially distressed firm - a classification that would require it to submit a business improvement plan.

Malaysia has also extended the relief to other companies which have been hit by the pandemic.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show